Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

L19IL2/L19TNF in patients with cutaneous squamous cell carcinoma Recruiting

2025-523231-19-00 Cutaneous Squamous Cell Carcinoma 4 2026-04-27
Phase 1 trial of valemetostat and darolutamide in mCRPC Recruiting

2025-522512-16-00 Metastatic Castration Resistant Prostate Cancer (mCRPC) 3 2026-04-23
MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors… Recruiting

2023-507485-10-00 advanced breast cancer 9 2026-04-21
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab. Recruiting

2025-521639-34-00 • Non-small cell lung cancer (Stage III, unresectable) 3 2026-04-20
A clinical study of MK-1084 with other treatments for non-small cell lung cancer (MK-3475-01F) Recruiting

2024-512248-47-00 Non-small Cell Lung Cancer (NSCLC) 9 2026-04-15
A Study to Test Inavolisib Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting

2025-521327-67-00 Metastatic Castration-Resistant Prostate Cancer 4 2026-04-13
A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer Recruiting

2025-524168-39-00 Platinum-Resistant ovarian cancer 1 2026-04-13
C6001001 - A Study to Learn about the Study Medicine PF-08052667 in People with Bladder Cancer. Recruiting

2025-521756-39-00 Non-muscle invasive bladder cancer (NMIBC) 1 2026-04-09
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors Recruiting

2025-523686-15-00 Advanced or Metastatic Solid Tumors 1 2026-04-08
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulve… Recruiting

2025-523013-28-00 Endocrine-Resistant Hormone-Receptor-Positive, HER2-Neg 4 2026-04-07
Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting

2025-522279-27-00 Newly Diagnosed AML with an NPM1 mutation 5 2026-04-02
A clinical study of V940 in people with non-small cell lung cancer (V940-013) Recruiting

2025-520902-37-00 Non-small cell lung cancer stage IV 4 2026-04-01
Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or V… Recruiting

2025-521966-91-00 Refractory Metastatic Breast Cancer with Liver Dominant 4 2026-03-31
A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers Recruiting

2025-522402-21-00 Advanced solid tumors (cutaneous melanoma, mucosal mela 1 2026-03-27
A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit… Recruiting

2025-523204-68-00 HER2-positive breast cancer 4 2026-03-25
A Phase 1 Study of IM-1021 in Participants with Advanced Cancer Recruiting

2025-523160-20-00 Advanced solid tumors 1 2026-03-23
Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 NPM1-m and KMT2A-r Acute Myeloid Leukemia 5 2026-03-19
ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting

2025-521884-12-00 First line triple-negative breast cancer (TNBC) 5 2026-03-19
A clinical study of MK-3120 in people with bladder cancer (MK-3120-003) Recruiting

2025-520467-40-00 High-risk non-muscle invasive bladder cancer (NMIBC) wi 9 2026-03-16
A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refrac… Recruiting

2024-519537-29-00 Acute Myeloid Leukemia and Myelodysplastic Syndrome 1 2026-03-13
Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting

2024-519444-33-00 HER2-expressing endometrial cancer (IHC 3+/2+) 5 2026-03-12
Visugromab, nivolumab and lenvatinib compared to double placebo and lenvatinib in unresectable or metastatic hepatocellular carcinoma post a… Recruiting

2025-520675-86-00 Unresectable or Metastatic Hepatocellular Carcinoma and 4 2026-03-10
A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung can… Recruiting

2025-522437-65-00 small-cell lung cancer 4 2026-03-06
A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies Recruiting

2024-516476-15-00 Advanced gastrointestinal stromal tumor (GIST) 9 2026-03-04